Skip to main content Back to Top
Advertisement

1/8/2022

Ropivacaine Injection

Products Affected - Description

    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0288-10
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0285-65
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0285-64
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0286-20
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL Steripak plastic ampule, 5 count, NDC 63323-0286-31
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL vial, 25 count, NDC 63323-0287-21
    • Ropivacaine injection, AuroMedics, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0200-10
    • Ropivacaine injection, AuroMedics, 10 mg/mL, 20 mL vial, 25 count, NDC 55150-0201-20
    • Ropivacaine injection, AuroMedics, 2 mg/mL, 100 mL infusion bottle, 25 count, NDC 55150-0196-99
    • Ropivacaine injection, AuroMedics, 2 mg/mL, 20 mL vial, 25 count, NDC 55150-0195-20
    • Ropivacaine injection, AuroMedics, 5 mg/mL, 20 mL vial, 25 count, NDC 55150-0197-20
    • Ropivacaine injection, AuroMedics, 5 mg/mL, 30 mL vial, 25 count, NDC 55150-0198-30
    • Ropivacaine injection, AuroMedics, 7.5 mg/mL, 20 mL vial, 25 count, NDC 55150-0199-20
    • Ropivacaine injection, Pfizer, 2 mg/mL, 10 mL vial, 10 count, NDC 00409-9300-10
    • Ropivacaine injection, Pfizer, 2 mg/mL, 20 mL vial, 10 count, NDC 00409-9300-20
    • Ropivacaine injection, Sagent, 2 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0671-82
    • Ropivacaine injection, Sagent, 2 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0671-87
    • Ropivacaine injection, Sagent, 5 mg/mL, 200 mL premixed bag, 10 count, NDC 25021-0652-87
    • Ropivacaine injection, Somerset Therapeutics LLC, 5 mg/mL, 30 mL vial, 1 count, NDC 70069-0064-01

Reason for the Shortage

    • Akorn had ropivacaine on shortage due to increased demand.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has Naropin on shortage due to increased demand and manufacturing delays.
    • Pfizer has ropivacaine on shortage due to increase demand.
    • Sagent had ropivacaine on shortage due to manufacturing delays
    • Somerset Therapeutics has ropivacaine 5 mg/mL 30 mL vials available.

Available Products

    • Naropin injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0288-11
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0288-20
    • Naropin injection, Fresenius Kabi, 10 mg/mL, 20 mL vial, 25 count, NDC 63323-0288-21
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL Steripak plastic ampule, 5 count, NDC 63323-0285-10
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 10 mL vial, 25 count, NDC 63323-0285-13
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 100 mL premixed bag, 1 count, NDC 63323-0285-61
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0285-20
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 25 count, NDC 63323-0285-23
    • Naropin injection, Fresenius Kabi, 2 mg/mL, 200 mL premixed bag, 1 count, NDC 63323-0285-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 100 mL infusion bottle, 1 count, NDC 63323-0286-00
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 20 mL vial, 25 count, NDC 63323-0286-23
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 200 mL infusion bottle, 1 count, NDC 63323-0286-63
    • Naropin injection, Fresenius Kabi, 5 mg/mL, 30 mL vial, 25 count, NDC 63323-0286-35
    • Naropin injection, Fresenius Kabi, 7.5 mg/mL, 20 mL Steripak plastic ampule, 5 count, NDC 63323-0287-20
    • Ropivacaine injection, Akorn, 5 mg/mL, 30 mL vial, 1 count, NDC 17478-0081-30
    • Ropivacaine injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9263-10
    • Ropivacaine injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-9303-10
    • Ropivacaine injection, Pfizer, 10 mg/mL, 20 mL vial, 10 count, NDC 00409-9303-20
    • Ropivacaine injection, Pfizer, 5 mg/mL, 30 mL vial, 10 count, NDC 00409-9301-30
    • Ropivacaine injection, Pfizer, 7.5 mg/mL, 20 mL vial, 10 count, NDC 00409-9302-20
    • Ropivacaine injection, Sagent, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0652-82

Estimated Resupply Dates

    • AuroMedics has all ropivacaine presentations on back order and the company cannot estimate a release date.
    • Fresenius Kabi has Naropin 2 mg/mL 100 mL and 200 mL bottles on back order and the company estimates a release date of late-January to early-February 2022 for the 100 mL bottles and late-January 2022 for the 200 mL bottles. The 7.5 mg/mL 20 mL vials are on back order and the company estimates a release date of late-February 2022. The 5 mg/mL 20 mL Steripak ampules and 10 mg/mL 20 mL Steripak ampules are on back order and the company cannot estimate a release date. There are short-dated 5 mg/mL 30 mL Steripak ampules available with an expiration date of < 6 months.
    • Pfizer has ropivacaine 2 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date of January 2022.
    • Sagent has short-dated ropivacaine 5 mg/mL 200 mL premixed bags available with an expiration date of February 2022. The 2 mg/mL 100 mL and 200 mL premixed bags are on limited allocation.
    • Somerset has ropivacaine 5 mg/mL 30 mL vials on back order and the company cannot estimate a release date.

Updated

Updated January 8, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.